Eton Pharmaceuticals Inc expected to post breakeven results a share - Earnings Preview

Eton Pharmaceuticals

14/03/2025 13:10

Eton Pharmaceuticals Inc ETON.OQ ETON.O is expected to show a rise in quarterly revenue when it reports  results on March 18 for the period ending December 31 2024

The Deer Park Illinois-based  company is expected to report a 44.0% increase in revenue to $10.53 million from $7.31 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Eton Pharmaceuticals Inc is for breakeven results per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Eton Pharmaceuticals Inc is $23.00​, above​ its last closing price of $14.60. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.01
-0.01
0.03
Beat
400
Jun. 30 2024
-0.07
-0.07
-0.12
Missed
-71.4
Mar. 31 2024
-0.07
-0.04
-0.03
Beat
33.3​
Dec. 31 2023
-0.04
-0.04
-0.09
Missed
-125
​​Sep. 30 2023
-0.10
-0.10
-0.02
Beat
80
Jun. 30 2023
-0.09
-0.09
0.15
Beat
266.7​
Mar. 31 2023
-0.14
-0.14
-0.10
Beat
28.6
Dec. 31 2022
0.01
0.01
0.04
Beat
300

This summary was machine generated March 14 at 13:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)